Company news

PTC Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program

November 3, 2026

PTC Therapeutics to Participate in Upcoming Investor Conferences

November 2, 2026

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 30, 2026

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

October 29, 2026

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

October 15, 2026

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

September 21, 2026

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

August 24, 2026

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

August 12, 2026

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

July 30, 2026

PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026

July 16, 2026

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes

June 15, 2026

PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes

June 15, 2026

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 7, 2026

Ardena Strengthens Executive Team to Drive its Next Phase of Growth

May 4, 2026

PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

April 28, 2026

PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026

April 21, 2026

PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors

March 24, 2026

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

February 19, 2026

PTC Therapeutics Provides Regulatory Update on Translarna™

February 12, 2026

PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026

February 5, 2026

PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference

January 12, 2026

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 8, 2026

PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan

December 21, 2025

PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 17, 2025

PTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

December 10, 2025

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

December 1, 2025

PTC Therapeutics to Host R&D Day

November 19, 2025

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 3, 2025

PTC Therapeutics to Participate at Upcoming Investor Conferences

October 30, 2025

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results

October 20, 2025

RareMed Announces Expansion of Relationship with PTC Therapeutics

September 2, 2025

PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA

August 18, 2025

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 6, 2025

Orsini Selected as Specialty Pharmacy Partner for PTC Therapeutics' SEPHIENCE™ (sepiapterin)

July 30, 2025

PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

July 27, 2025

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results

July 20, 2025

Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

June 22, 2025

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 5, 2025

PTC518 PIVOT-HD Study Achieves Primary Endpoint

May 4, 2025

PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

April 24, 2025

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results

April 16, 2025

PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe

March 27, 2025

PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies

March 19, 2025

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

February 26, 2025

PTC Therapeutics to Participate in Upcoming Investor Conferences

February 19, 2025

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

February 18, 2025

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

February 12, 2025

PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference

January 12, 2025

PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 22, 2024

PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia

December 18, 2024

Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 33 decks. Every deck is listed under its year.